Credo CEO Bill Brennan sold 16,672 ordinary shares on September 14 at prices between $150.39 and $153.39, worth about $2.53 million.
Credo Technology Group Holding (CRDO) chief executive William Joseph Brennan sold 16,672 ordinary shares in open-market transactions on September 14, according to a Form 4 filed with the Securities and Exchange Commission. The combined value of the sales was about $2.53 million.
Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.
Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.
Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.
VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.
